Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives Average Rating of “Hold” from Analysts

Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) have earned a consensus recommendation of “Hold” from the eleven analysts that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and six have given a buy rating to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $40.6667.

AGIO has been the subject of several research analyst reports. JPMorgan Chase & Co. increased their target price on shares of Agios Pharmaceuticals from $20.00 to $25.00 and gave the stock a “neutral” rating in a research note on Tuesday, January 6th. Truist Financial boosted their price target on shares of Agios Pharmaceuticals from $32.00 to $38.00 and gave the company a “buy” rating in a research note on Wednesday, December 24th. Leerink Partners upped their price objective on shares of Agios Pharmaceuticals from $34.00 to $40.00 and gave the stock an “outperform” rating in a report on Friday, December 26th. Bank of America increased their price objective on shares of Agios Pharmaceuticals from $32.00 to $34.00 and gave the stock a “buy” rating in a research report on Wednesday, December 24th. Finally, Citigroup boosted their target price on Agios Pharmaceuticals from $38.00 to $46.00 and gave the company a “buy” rating in a research report on Thursday, March 5th.

Insiders Place Their Bets

In other news, insider Krishnan Viswanadhan sold 2,959 shares of Agios Pharmaceuticals stock in a transaction on Thursday, March 5th. The stock was sold at an average price of $27.80, for a total value of $82,260.20. Following the completion of the sale, the insider directly owned 5,141 shares of the company’s stock, valued at approximately $142,919.80. The trade was a 36.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Tsveta Milanova sold 2,872 shares of the business’s stock in a transaction on Monday, January 5th. The shares were sold at an average price of $27.02, for a total value of $77,601.44. Following the completion of the sale, the insider owned 34,793 shares in the company, valued at $940,106.86. This represents a 7.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 4.93% of the company’s stock.

Institutional Trading of Agios Pharmaceuticals

Several hedge funds have recently made changes to their positions in AGIO. T. Rowe Price Investment Management Inc. acquired a new position in shares of Agios Pharmaceuticals in the fourth quarter valued at approximately $25,000. Assetmark Inc. lifted its holdings in Agios Pharmaceuticals by 37.9% during the 4th quarter. Assetmark Inc. now owns 1,317 shares of the biopharmaceutical company’s stock worth $36,000 after buying an additional 362 shares in the last quarter. NewEdge Advisors LLC acquired a new stake in Agios Pharmaceuticals during the 1st quarter worth approximately $40,000. First Horizon Corp purchased a new position in Agios Pharmaceuticals in the 3rd quarter valued at approximately $45,000. Finally, Caitong International Asset Management Co. Ltd acquired a new position in shares of Agios Pharmaceuticals in the fourth quarter worth $49,000.

Agios Pharmaceuticals Trading Up 0.6%

Shares of NASDAQ:AGIO opened at $29.61 on Tuesday. The business has a 50-day moving average price of $28.33 and a 200 day moving average price of $32.19. The company has a market capitalization of $1.73 billion, a price-to-earnings ratio of -4.16 and a beta of 0.89. Agios Pharmaceuticals has a 12-month low of $22.24 and a 12-month high of $46.00.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.